#Headlines

India halts production at factory linked to Gambia deaths

Oct 13, 2022, 11:14 AM

NEW DELHI, Oct 12 (Reuters) - Indian health authorities said on Wednesday they had halted all production at the main factory of Maiden Pharmaceuticals near New Delhi after a WHO report that its cough syrups exported to Gambia may be linked to the deaths of dozens of children there. Known as a 
"pharmacy of the world"
 India supplies 45% of all generic medicines to Africa.

 The deaths of 69 children in Gambia *_- one of the worst such incidents involving drugs from India - have come as a blow to the industry whose exports more than doubled in the last decade to hit $24.5 billion last fiscal year.

 Indian authorities inspected the Maiden factory in the state of Haryana four times this month and suspended all manufacturing activities there on Tuesday "on grounds of deficiencies found in location inspection".

 Haryana's health minister said an inspection conducted jointly by state and federal officials found 12 "FLAWS"

  "Keeping this in view, the entire production of the company has been banned and notice has also been issued," minister Anil Vij said in a statement, referring to Maiden's main factory in Sonipat district.